Literature DB >> 3922659

Concentration-effect relationships of valproic acid.

D W Chadwick.   

Abstract

Valproic acid is an effective broad spectrum anticonvulsant drug. It has a relatively short half-life, and large diurnal fluctuations in serum concentrations occur, thus making it difficult to define clear relationships between individual serum concentrations and either therapeutic or adverse effects. The value of routine 'one-off' measurements of valproate in clinical practice are further reduced by the absence of a clearly defined dose-related neurotoxicity syndrome. The often quoted therapeutic range for valproate of 50 to 100 mg/L has therefore to be regarded with some circumspection, although available data does suggest an increased incidence of adverse reactions with serum concentrations above 100 mg/L.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922659     DOI: 10.2165/00003088-198510020-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  38 in total

1.  Determination of lower fatty acids, particularly the anti-epileptic dipropyl-acetic acid, in biological materials by means of micro diffusion and gas chromatography.

Authors:  J W Meijer; L Hessing-Brand
Journal:  Clin Chim Acta       Date:  1973-01-24       Impact factor: 3.786

2.  The treatment of childhood epilepsy with sodium valproate.

Authors:  D Haigh; W I Forsythe
Journal:  Dev Med Child Neurol       Date:  1975-12       Impact factor: 5.449

Review 3.  Serum levels of anticonvulsant drugs. Interpretation and clinical value.

Authors:  E H Reynolds
Journal:  Pharmacol Ther       Date:  1980       Impact factor: 12.310

4.  Preliminary observations on valproic acid kinetics in patients with epilepsy.

Authors:  S I Johannessen
Journal:  Arzneimittelforschung       Date:  1977

5.  Disposition of sodium valproate in epileptic patients.

Authors:  E Perucca; G Gatti; G M Frigo; A Crema; S Calzetti; D Visintini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

6.  Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors:  F Schobben; E van der Kleijn; F J Gabreëls
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

Review 7.  Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy.

Authors:  R M Pinder; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-02       Impact factor: 9.546

8.  The delayed effect of sodium valproate on the photoconvulsive response in man.

Authors:  A J Rowan; C D Binnie; C A Warfield; H Meinardi; J W Meijer
Journal:  Epilepsia       Date:  1979-02       Impact factor: 5.864

9.  Sodium valproate: monotherapy and polytherapy.

Authors:  A Covanis; A K Gupta; P M Jeavons
Journal:  Epilepsia       Date:  1982-12       Impact factor: 5.864

10.  Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients.

Authors:  J L Herranz; R Arteaga; J A Armijo
Journal:  Epilepsia       Date:  1982-04       Impact factor: 5.864

View more
  20 in total

1.  Drugs pharmacokinetics in ICU patients: consequences of hypoalbuminemia upon drugs monitoring and dosing scheme.

Authors:  Franck Lagneau; Sébastien Perbet; Didier Delefosse; Anne Wernet; Jeanick Stocco; Jean Marty
Journal:  Intensive Care Med       Date:  2004-04-28       Impact factor: 17.440

2.  Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics.

Authors:  José L Herranz; Rosa Arteaga; Javier Adín; Juan A Armijo
Journal:  Eur J Clin Pharmacol       Date:  2006-08-02       Impact factor: 2.953

Review 3.  Epilepsy.

Authors:  D Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

4.  The effect of uridine diphosphate glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics in Indian patients with epilepsy: a pharmacogenetic approach.

Authors:  Murali Munisamy; Manjari Tripathi; Madhuri Behari; S Raghavan; D C Jain; Barghavi Ramanujam; Karthik Arumugam; Thiyagu Rajakannan; Surulivel Rajan Mallayasamy; Vivekanandhan Subbiah
Journal:  Mol Diagn Ther       Date:  2013-10       Impact factor: 4.074

Review 5.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

6.  Synthesis and evaluation of amino analogues of valproic acid.

Authors:  K R Scott; S Adesioye; P B Ayuk; I O Edafiogho; D John; P Kodwin; T Maxwell-Irving; J A Moore; J M Nicholson
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

Review 7.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 9.  The role of therapeutic drug monitoring in improving the cost effectiveness of anticonvulsant therapy.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

10.  Decreased plasma protein binding of valproate in patients with acute head trauma.

Authors:  G D Anderson; B E Gidal; R J Hendryx; A B Awan; N R Temkin; A J Wilensky; H R Winn
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.